GSK quad flu vaccine to shake up Germany and UK
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline is poised to take a bigger slice of the influenza prevention market, which, Datamonitor says is worth $3.5 billion in the US, Japan and EU big five. Germany and the UK have approved the quadrivalent flu vaccine under the decentralized procedure and GSK expects to be able to compete in the 2013/13 flu season.